CORCEPT THERAPEUTICS INC (CORT) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does CORCEPT THERAPEUTICS INC Do?
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California. CORCEPT THERAPEUTICS INC (CORT) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Joseph K. Belanoff and employs approximately 300 people, headquartered in MENLO PARK, California. With a market capitalization of $4.5B, CORT is one of the notable companies in the Healthcare sector.
CORCEPT THERAPEUTICS INC (CORT) Stock Rating — Reduce (April 2026)
As of April 2026, CORCEPT THERAPEUTICS INC receives a Reduce rating with a composite score of 28.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CORT ranks #2,944 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CORCEPT THERAPEUTICS INC ranks #418 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
CORT Stock Price and 52-Week Range
CORCEPT THERAPEUTICS INC (CORT) currently trades at $42.14. The stock lost $0.11 (0.3%) in the most recent trading session. The 52-week high for CORT is $117.33, which means the stock is currently trading -64.1% from its annual peak. The 52-week low is $28.66, putting the stock 47.0% above its annual trough. Recent trading volume was 843K shares, suggesting relatively thin trading activity.
Is CORT Overvalued or Undervalued? — Valuation Analysis
CORCEPT THERAPEUTICS INC (CORT) carries a value factor score of 39/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 36.18x, compared to the Healthcare sector average of 23.63x — a premium of 53%. The price-to-book ratio stands at 7.02x, versus the sector average of 2.75x. The price-to-sales ratio is 5.98x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, CORT trades at 51.03x EV/EBITDA, versus 6.34x for the sector.
At current multiples, CORCEPT THERAPEUTICS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
CORCEPT THERAPEUTICS INC Profitability — ROE, Margins, and Quality Score
CORCEPT THERAPEUTICS INC (CORT) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 19.4%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 14.9% versus the sector average of -33.1%.
On a margin basis, CORCEPT THERAPEUTICS INC reports gross margins of 98.2%, compared to 71.5% for the sector. The operating margin is 11.6% (sector: -66.1%). Net profit margin stands at 16.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 26.8% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
CORT Debt, Balance Sheet, and Financial Health
CORCEPT THERAPEUTICS INC has a debt-to-equity ratio of 30.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.14x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $125M.
CORT has a beta of 1.34, meaning it is more volatile than the broader market — a $10,000 investment in CORT would be expected to move 33.7% more than the S&P 500 on any given day. The stability factor score for CORCEPT THERAPEUTICS INC is 17/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
CORCEPT THERAPEUTICS INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, CORCEPT THERAPEUTICS INC reported revenue of $742M and earnings per share (EPS) of $0.19. Net income for the quarter was $123M. Gross margin was 98.2%. Operating income came in at $87M.
In Q3 2025, CORCEPT THERAPEUTICS INC reported revenue of $208M and earnings per share (EPS) of $0.19. Net income for the quarter was $20M. Gross margin was 97.8%. Revenue grew 13.7% year-over-year compared to Q3 2024. Operating income came in at $10M.
In Q2 2025, CORCEPT THERAPEUTICS INC reported revenue of $194M and earnings per share (EPS) of $0.33. Net income for the quarter was $35M. Gross margin was 98.2%. Revenue grew 18.7% year-over-year compared to Q2 2024. Operating income came in at $27M.
In Q1 2025, CORCEPT THERAPEUTICS INC reported revenue of $157M and earnings per share (EPS) of $0.19. Net income for the quarter was $21M. Gross margin was 98.5%. Revenue grew 7.1% year-over-year compared to Q1 2024. Operating income came in at $3M.
Over the past 8 quarters, CORCEPT THERAPEUTICS INC has demonstrated a growth trajectory, with revenue expanding from $147M to $742M. Investors analyzing CORT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
CORT Dividend Yield and Income Analysis
CORCEPT THERAPEUTICS INC (CORT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
CORT Momentum and Technical Analysis Profile
CORCEPT THERAPEUTICS INC (CORT) has a momentum factor score of 12/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 3/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
CORT vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, CORCEPT THERAPEUTICS INC (CORT) ranks #418 out of 838 stocks based on the Blank Capital composite score. This places CORT in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing CORT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CORT vs S&P 500 (SPY) comparison to assess how CORCEPT THERAPEUTICS INC stacks up against the broader market across all factor dimensions.
CORT Next Earnings Date
No upcoming earnings date has been announced for CORCEPT THERAPEUTICS INC (CORT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy CORT? — Investment Thesis Summary
The quantitative profile for CORCEPT THERAPEUTICS INC suggests caution. The value score of 39/100 indicates premium valuation. Momentum is weak at 12/100, a headwind for near-term performance. High volatility (stability score 17/100) increases portfolio risk.
In summary, CORCEPT THERAPEUTICS INC (CORT) earns a Reduce rating with a composite score of 28.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CORT stock.
Related Resources for CORT Investors
Explore more research and tools: CORT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CORT head-to-head with peers: CORT vs AZN, CORT vs SLGL, CORT vs VMD.